Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40524802.
- Also identified by DOI 10.1016/j.eclinm.2025.103282 and PMC identifier 12169793.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed to evaluate the efficacy and safety of adjuvant pembrolizumab in patients with completely resected stage I lung adenocarcinoma with micropapillary or solid-pattern (MPSOL). This was a single-center, single-arm phase 2 study (ClinicalTrials.gov identifier: NCT03254004). Key eligibility criteria included patients with stage I lung adenocarcinoma (per the American Joint Committee on Cancer 8th edition; primary tumor of <4 cm and without nodal metastasis), characterized by MPSOL histological subtype upon postsurgical pathological examination Patients were treated with pembrolizumab 200 mg every 3 weeks for 1 year or until disease recurrence or intolerable toxicity. The primary endpoint was 3-year disease-free survival (DFS), defined as the time from surgery to recurrence or death from any cause. Secondary endpoints included overall survival and safety. Between September 17, 2018, and February 10, 2022, 70 patients were enrolled. At a median follow-up of 45·0 months, the 3-year disease-free survival (DFS) was 83·2%, meeting the survival endpoint of >80%. Patients with <i>EGFR</i> mutations showed significantly poorer DFS than those with <i>EGFR</i> wild-type (hazard ratio [HR]: 5·01 [95% confidence interval (CI): 1·11-22·70], <i>P</i> = 0·036), although no significant differences were noted according to age, smoking status, tumor size, and PD-L1 tumor proportion score. Grade 3 or 4 treatment-related adverse events (AEs) occurred in 6 patients (8·6%). Thirteen AEs led to treatment discontinuation and the majority of these AEs resolved upon discontinuation and subsequent steroid treatment. Adjuvant pembrolizumab exhibited promising clinical efficacy in patients with stage I lung MPSOL, particularly those with EGFR-wild type, and exhibited tolerable safety. Merk Sharp & Dohme (MSD). The funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.